Evogene Ltd. (TLV:EVGN)
152.00
+1.50 (1.00%)
Sep 10, 2026, 5:24 PM IDT
Evogene Employees
Evogene had 38 employees as of June 30, 2026. The number of employees decreased by 14 or -26.92% since the number was reported on December 31, 2025.
Employees
38
Change
-14
Growth
-26.92%
Revenue / Employee
129.90K ILS
Profits / Employee
-711.30K ILS
Market Cap
23.78M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 38 | -14 | -26.92% | 38 | 0 |
| Dec 31, 2025 | 52 | -65 | -55.56% | 52 | 0 |
| Dec 31, 2024 | 117 | -25 | -17.61% | 117 | 0 |
| Dec 31, 2023 | 142 | 5 | 3.65% | 142 | 0 |
| Dec 31, 2022 | 137 | -4 | -2.84% | 137 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bonus BioGroup | 42 |
| BioLineRx | 24 |
| Matricelf | 15 |
| Purple Biotech | 10 |
| XTL Biopharmaceuticals | 5 |
| Can-Fite BioPharma | 5 |
| BioLight Life Sciences | 4 |
Evogene News
- 13 days ago - Evogene responds to latest communication from L.I.A. Pure Capital, Invest-Pro - TheFly
- 13 days ago - Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward - PRNewsWire
- 17 days ago - EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026 - Business Wire
- 19 days ago - Evogene (EVGN) Q2 2026 Earnings Call Transcript - The Motley Fool
- 19 days ago - Evogene’s director nominees recommended by ISS and Glass Lewis - TheFly
- 19 days ago - Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees - PRNewsWire
- 25 days ago - Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35% - AlphaStreet
- 25 days ago - Evogene Q2 Loss Narrows As AI Transformation Drives Strategic Progress - Nasdaq